Objectives: To present recommendations and supporting literature for RBC transfusions in critically ill children supported with extracorporeal membrane oxygenation, ventricular assist devices, or renal replacement therapy. Design: Consensus conference series of international, multidisciplinary experts in RBC transfusion management of critically ill children. Methods: The panel of 38 experts developed evidence-based, and when evidence was lacking, expert-based clinical recommendations as well as research priorities for RBC transfusions in critically ill children. The extracorporeal membrane oxygenation/ ventricular assist device/renal replacement therapy subgroup included six experts. We conducted electronic searches of the PubMed, EMBASE, and Cochrane Library databases from 1980
to May 2017, using medical subject heading terms and text words to define concepts of RBC transfusion, extracorporeal membrane oxygenation, ventricular assist device, and renal replacement therapy. We used a standardized data extraction form to construct evidence tables and graded the evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations developed and supporting literature were reviewed and scored by all panel members. Agreement was obtained using the Research and Development/UCLA Appropriateness Method. Results: For inpatients requiring extracorporeal membrane oxygenation, ventricular assist device, or renal replacement therapy support, there was expert agreement (> 80%) on five good practice statements aimed to improve accuracy and uniform reporting of RBC transfusion data in pediatric extracorporeal membrane oxygenation, ventricular assist device, and renal replacement therapy studies and quality improvement projects; four clinical recommendations of physiologic metrics and biomarkers of oxygen delivery, in addition to hemoglobin concentration, to guide RBC transfusion, acknowledging insufficient evidence to recommend specific RBC transfusion strategies; and eight research recommendations. Conclusions: Further research surrounding indications, risks, benefits, and alternatives to RBC transfusion in children on extracorporeal devices is clearly needed. Using a structured literature review and grading process, the Transfusion and Anemia Expertise Initiative panel concluded that there is currently insufficient evidence to recommend specific RBC transfusion variables in children requiring extracorporeal membrane oxygenation, ventricular assist device, or renal replacement therapy support. (Pediatr Crit Care Med 2018; 19:S157-S162) Key Words: blood; extracorporeal life support; pediatric critical care; renal replacement therapy; transfusion; ventricular assist device T he use of extracorporeal devices in children with cardiac, respiratory, and/or renal failure has increased significantly over the last 2 decades, partly driven by continued improvement in biocompatibility and safety features that allow for deployment of such devices in critically ill infants and children (1) (2) (3) . With the increase in use of extracorporeal support, concern has also increased over the burden of RBC transfusion in these patients as well as RBC transfusion-associated morbidity and cost.
Exposure to RBC administration in children with extracorporeal devices occurs in several ways. Neonates and small children are exposed to transfused RBCs through priming of the device at initiation of support as well as when devices need to be replaced due to thrombosis, malfunction, or other indications. Once on the device, RBCs may be transfused for active hemorrhage, which is estimated to occur in as many as one third of extracorporeal membrane oxygenation (ECMO) patients and one third of ventricular assist devices (VADs) patients (4, 5) . Last, RBCs are often transfused in children on ECMO or VADs to maintain hemoglobin concentrations at preset levels based on varied institutional practices with the presumed goal of optimizing oxygen delivery. There are no published evidence-based guidelines to direct clinicians on when to transfuse RBCs in patients supported on extracorporeal devices in the absence of active bleeding. Therefore, large variability in practice exists (6) . We present recommendations for clinical practice as supported by the review of the pediatric literature on indications for RBC transfusion in critically ill children supported with ECMO, VADs, or renal replacement therapy (RRT). Recommendations for future research are also provided.
METHODS
The details of the methodology are described elsewhere in this supplement of Pediatric Critical Care Medicine (7) . Briefly, we searched PubMed, EMBASE, and Cochrane Library from 1980 to December 2015, with an update in May 2017, using a combination of medical subject heading terms and text words to define concepts of RBC transfusion, ECMO, VAD, and RRT. We searched references from identified articles for additional publications. Two authors reviewed all citations independently. We used a standardized data extraction form to construct evidence tables and graded the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. A panel of 38 experts from 29 academic institutions in eight countries met over the course of 2 years to develop evidence-based and, when evidence was lacking, expert-based recommendations for RBC transfusion in critically ill children. Recommendations developed and supporting literature were reviewed and scored by all panel members, using the Research and Development/ UCLA Appropriateness Method. All recommendations reached agreement (> 80%). Final recommendations for RBC transfusion in critically ill children with ECMO, VAD, and RRT devices were divided into three categories: good practice statements, clinical recommendations, and research recommendations.
RESULTS
Using the search strategy described above, we retrieved 2,782 abstracts. Eighty-one papers were retained for the full-text evaluation, 21 papers included, among which 13 papers were selected and used in the final process to generate the following good practice statements, clinical and research recommendations, and are presented in the Supplemental Digital Content 1 (http://links.lww.com/PCC/A691).
Good Practice Statements

In critically ill children on ECMO, we recommend
reporting Hb concentration, rather than hematocrit, for RBC transfusion threshold algorithms.
Consensus panel expertise, 97% Agreement, n = 35, median 8 (IQR 8-9)
Pediatric Critical Care Medicine www.pccmjournal.org
S159
Rationale. Historically, most ECMO publications used hematocrit thresholds for RBC transfusions (8) (9) (10) (11) (12) (13) (14) (15) . However, in the current era, RBC transfusion research in critical care is overwhelmingly conducted using hemoglobin (not hematocrit) thresholds, including in pediatric populations (16, 17) . Using hemoglobin to align RBC transfusion threshold reporting in ECMO patients with RBC transfusion threshold reporting in critically ill non-ECMO populations will allow on and off ECMO comparisons within these populations (e.g., acute respiratory distress syndrome, cardiac arrest, cardiogenic shock, etc). Indeed, some adult ECMO centers have been reporting hemoglobin thresholds for transfusion based on extrapolation of evidence from non-ECMO critically ill populations (10 Rationale. ECMO patients receive large amounts of RBCs, ranging on average from 42 mL/kg/d to up to 105 mL/kg/d (8, 9, 11, 18) . The number of donor exposures in ECMO patients, therefore, ranges from a median of 1.4 to 10.9 per ECMO course (8, (12) (13) (14) (15) 19) . Indications for RBC transfusion are primarily based on expert Extracorporeal Life Support Organization clinical guidelines, last updated in 2013, recommending to maintain hematocrit above 40% during ECMO, in an effort to "optimize oxygen delivery while allowing the lowest reasonable ECMO circuit flow" (20) . However, ECMO medical directors in a recent survey reported lower hematocrit thresholds for RBC transfusion: medians of 35% (range, 25-40%) for pediatric-only programs and 30% (range, 20-40%) for adult-only and mixed adult and pediatric programs (6) .
Adult ECMO centers are reporting adoption of restrictive transfusion strategies based on evidence in critically ill patients, with hemoglobin thresholds as low as 7 g/dL, without adverse effects noted (10, 19) . As pediatric ECMO patients were excluded from pediatric trials of restrictive versus liberal RBC transfusion strategies (14) , evidence is insufficient to support a specific hemoglobin or hematocrit threshold for RBC transfusions in this population. Furthermore, pediatric ECMO patients may have varying requirements for RBC transfusion based on age, variable physiology of the underlying disease, or mode of ECMO support (venoarterial vs venovenous). Adhering to a normal/near-normal hemoglobin/hematocrit threshold without considering adequacy of systemic and/or regional oxygen delivery (e.g., systemic oxygen saturation, mixed venous saturation, lactate, cerebral oximetry, somatic oximetry, etc) could expose pediatric ECMO patients to unnecessary RBC transfusions. Although pediatric evidence is scant, Fiser et al (8) showed in a single center pediatric ECMO study (n = 45 patients with a median of nine RBC transfusion events per patient, range, 1-57) that a majority (> 70%) of transfusions were administered when systemic mixed venous oxygen saturation was adequate. In the same study, the authors showed that tissue oxygenation measures, including mixed venous saturation and cerebral oximetry, were not significantly altered following RBC transfusions. Only 31 of 617 RBC transfusions (5%) administered resulted in an increase in mixed venous saturation of greater than 5%, whereas an increase in cerebral regional oxygen saturation of more than 5% was only observed in 53 of 617 transfusions (9%) (8) . "GRADE 2C for this recommendation was based on the pediatric literature discussed above, with downgrading for risk of bias, indirectness, and residual confounding." 8.7 In critically ill children on ECMO, there is insufficient evidence to recommend a specific RBC transfusion decision-making strategy using physiologic-based metrics and biomarkers. Rationale. There are no published prospective studies on optimal hemoglobin and/or physiologic transfusion thresholds in critically ill children with VADs. Children with VADs were excluded from the major pediatric critical care randomized controlled trial of a restrictive versus liberal transfusion strategy (16) . The American Heart Association guidelines for mechanical circulatory support in the ambulatory and community setting emphasize the potentially detrimental role of RBC transfusion in the "bridge-to-transplant" patient due to increase in anti-human leuckocyte antigen (HLA) antibodies that could complicate donor matching, recommending that transfusion should be "targeted to symptomatic patients only" (22) .
Providers are cautioned to avoid anemia in mechanical circulatory support patients, due to its association with increased morbidity and mortality in this population (22, 23) . In the critical care environment, similar to ECMO patients, children with VADs receive large volumes of RBCs. Stiller et al (19) reported that in a single center where transfusion was guided by a hemoglobin threshold of 9 g/dL children received 17.2 mL RBCs/kg/d during the first 8 days of VAD support. In a different cohort, Guynes et al (24) reported that pediatric VAD patients in a single center received 676 mL RBCs/kg/patient during the entire VAD course; of note, transfusion triggers were not reported in this study. With regard to ABO and HLA sensitization, in two single center studies of pediatric mechanical circulatory support, 29% of patients developed ABO sensitization, and 43% of patients developed HLA sensitization (24, 25) . The volume of transfusions was not associated with development of sensitization, but small sample sizes and retrospective design were limitations noted for both studies (24, 25).
8.9
In critically ill children on RRT support, we recommend using the smallest circuit size that will provide adequate RRT, while minimizing a driver for RBC transfusion specific to RRT (i.e., loss of blood volume that arises with circuit dysfunction/replacement of the circuit).
Consensus panel expertise, 100% Agreement, n = 35, median 9 (IQR 8-9)
Rationale. There are no published prospective studies on the optimal hemoglobin and/or physiologic transfusion threshold for pediatric patients supported with RRT. The one way to avoid excess blood exposure is to minimize the circuit volume that has significant impact in the smaller (i.e., < 20 kg) children. Presently in the United States, the smallest RRT circuit volume is ~ 83 mL, making it a possibility to use in 10 kg children without a blood prime unless hemodynamics dictate otherwise. Outside of the United States, approved circuit volumes range from 60 mL, and miniaturized circuits are currently under study in the United Kingdom and Italy, with volumes of 14 mL (Newcastle Infant Dialysis and Ultrafiltration System [NIDUS]) and 27 mL (Cardio-Renal Pediatric Dialysis Emergency Machine [CARPEDIEM]).. Advances in miniature circuits as small as 3 mL are ongoing in Japan (26) (27) (28) . In addition to these small circuits, the volume of the vascular access (usually 2 mL for each access port) needs to be considered. This group of patients presents an additional challenge in having unpredictable renal synthesis of erythropoietin to stimulate hematopoiesis, potentially complicating transfusion needs. 
Research Recommendations
CONCLUSIONS
Using a structured literature review and grading process, the Transfusion and Anemia Expertise Initiative panel concluded there is currently insufficient evidence to recommend specific RBC transfusion variables in children requiring ECMO, VAD, or RRT support. Further research surrounding indications, risk, benefits, and alternatives to RBC transfusion in children on extracorporeal devices is needed to better establish hemoglobin and RBC-related strategies that optimize outcomes.
